FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382361489> ?p ?o ?g. }

• W4382361489 endingPage "115058" @default.
• W4382361489 startingPage "115058" @default.
• W4382361489 abstract "Rivaroxaban is a direct inhibitor of factor Xa, a member of direct oral anticoagulant group of drugs (DOACs). Despite being a widely extended alternative to vitamin K antagonists (i.e., acenocoumarol, warfarin) the interindividual variability of DOACs is significant, and may be related to adverse drug reaction occurrence or drug inefficacy, namely hemorrhagic or thromboembolic events. Since there is not a consistent analytic practice to monitor the anticoagulant activity of DOACs, previously reported polymorphisms in genes coding for proteins responsible for the activation, transport, or metabolism of DOACs were studied. The study population comprised 60 healthy volunteers, who completed two randomized, crossover bioequivalence clinical trials between two different rivaroxaban formulations. The effect of food, sex, biogeographical origin and 55 variants (8 phenotypes and 47 single nucleotide polymorphisms) in drug metabolizing enzyme genes (such as CYP2D6, CYP2C9, NAT2) and transporters (namely, ABCB1, ABCG2) on rivaroxaban pharmacokinetics was tested. Individuals dosed under fasting conditions presented lower tmax (2.21 h vs 2.88 h, β = 1.19, R2 =0.342, p = 0.012) compared to fed volunteers. NAT2 slow acetylators presented higher AUC∞ corrected by dose/weight (AUC∞/DW; 8243.90 vs 7698.20 and 7161.25 h*ng*mg /ml*kg, β = 0.154, R2 =0.250, p = 0.044), higher Cmax/DW (1070.99 vs 834.81 and 803.36 ng*mg /ml*kg, β = 0.245, R2 =0.320, p = 0.002), and lower tmax (2.63 vs 3.19 and 4.15 h, β = -0.346, R2 =0.282, p = 0.047) than NAT2 rapid and intermediate acetylators. No other association was statistically significant. Thus, slow NAT2 appear to have altered rivaroxaban pharmacokinetics, increasing AUC∞ and Cmax. Nonetheless, further research should be conducted to verify NAT2 involvement on rivaroxaban pharmacokinetics and to determine its clinical significance." @default.
• W4382361489 created "2023-06-29" @default.
• W4382361489 creator A5010008926 @default.
• W4382361489 creator A5010358276 @default.
• W4382361489 creator A5011415422 @default.
• W4382361489 creator A5023070833 @default.
• W4382361489 creator A5026681178 @default.
• W4382361489 creator A5033176608 @default.
• W4382361489 creator A5047342267 @default.
• W4382361489 creator A5056454945 @default.
• W4382361489 creator A5078396638 @default.
• W4382361489 creator A5084948431 @default.
• W4382361489 creator A5089347304 @default.
• W4382361489 creator A5092348659 @default.
• W4382361489 creator A5092348660 @default.
• W4382361489 creator A5092348661 @default.
• W4382361489 date "2023-09-01" @default.
• W4382361489 modified "2023-10-18" @default.
• W4382361489 title "NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers" @default.
• W4382361489 cites W1564607482 @default.
• W4382361489 cites W1762950170 @default.
• W4382361489 cites W1918208609 @default.
• W4382361489 cites W1972316851 @default.
• W4382361489 cites W1975157264 @default.
• W4382361489 cites W1981067019 @default.
• W4382361489 cites W1990249837 @default.
• W4382361489 cites W2033139608 @default.
• W4382361489 cites W2049501844 @default.
• W4382361489 cites W2064826963 @default.
• W4382361489 cites W2138509705 @default.
• W4382361489 cites W2148948931 @default.
• W4382361489 cites W2167182965 @default.
• W4382361489 cites W2305463040 @default.
• W4382361489 cites W2505087320 @default.
• W4382361489 cites W2559528249 @default.
• W4382361489 cites W2562778159 @default.
• W4382361489 cites W2562806729 @default.
• W4382361489 cites W2588108371 @default.
• W4382361489 cites W2621404381 @default.
• W4382361489 cites W2745301009 @default.
• W4382361489 cites W2770460146 @default.
• W4382361489 cites W2783540211 @default.
• W4382361489 cites W2951716367 @default.
• W4382361489 cites W3037797714 @default.
• W4382361489 cites W3114326816 @default.
• W4382361489 cites W3119634521 @default.
• W4382361489 cites W3175801695 @default.
• W4382361489 cites W3194623590 @default.
• W4382361489 cites W4213127162 @default.
• W4382361489 cites W4225127267 @default.
• W4382361489 cites W4293633679 @default.
• W4382361489 cites W4296025790 @default.
• W4382361489 doi "https://doi.org/10.1016/j.biopha.2023.115058" @default.
• W4382361489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37385211" @default.
• W4382361489 hasPublicationYear "2023" @default.
• W4382361489 type Work @default.
• W4382361489 citedByCount "1" @default.
• W4382361489 countsByYear W43823614892023 @default.
• W4382361489 crossrefType "journal-article" @default.
• W4382361489 hasAuthorship W4382361489A5010008926 @default.
• W4382361489 hasAuthorship W4382361489A5010358276 @default.
• W4382361489 hasAuthorship W4382361489A5011415422 @default.
• W4382361489 hasAuthorship W4382361489A5023070833 @default.
• W4382361489 hasAuthorship W4382361489A5026681178 @default.
• W4382361489 hasAuthorship W4382361489A5033176608 @default.
• W4382361489 hasAuthorship W4382361489A5047342267 @default.
• W4382361489 hasAuthorship W4382361489A5056454945 @default.
• W4382361489 hasAuthorship W4382361489A5078396638 @default.
• W4382361489 hasAuthorship W4382361489A5084948431 @default.
• W4382361489 hasAuthorship W4382361489A5089347304 @default.
• W4382361489 hasAuthorship W4382361489A5092348659 @default.
• W4382361489 hasAuthorship W4382361489A5092348660 @default.
• W4382361489 hasAuthorship W4382361489A5092348661 @default.
• W4382361489 hasBestOaLocation W43823614891 @default.
• W4382361489 hasConcept C104317684 @default.
• W4382361489 hasConcept C112705442 @default.
• W4382361489 hasConcept C126322002 @default.
• W4382361489 hasConcept C135763542 @default.
• W4382361489 hasConcept C142724271 @default.
• W4382361489 hasConcept C204787440 @default.
• W4382361489 hasConcept C22979827 @default.
• W4382361489 hasConcept C27081682 @default.
• W4382361489 hasConcept C2776301958 @default.
• W4382361489 hasConcept C2778661090 @default.
• W4382361489 hasConcept C2779161974 @default.
• W4382361489 hasConcept C2781344064 @default.
• W4382361489 hasConcept C2908647359 @default.
• W4382361489 hasConcept C33664856 @default.
• W4382361489 hasConcept C3946865 @default.
• W4382361489 hasConcept C42404028 @default.
• W4382361489 hasConcept C526171541 @default.
• W4382361489 hasConcept C55493867 @default.
• W4382361489 hasConcept C55775858 @default.
• W4382361489 hasConcept C62231903 @default.
• W4382361489 hasConcept C71924100 @default.
• W4382361489 hasConcept C86803240 @default.
• W4382361489 hasConcept C87813604 @default.
• W4382361489 hasConcept C98274493 @default.

• next